Faster Personalized Therapies
SeLux’s Next-Generation Phenotyping (NGP) platform will enable physicians to transition patients to personalized antibiotic therapies much more quickly – from one to four days earlier – than current state-of-the-art platforms, providing next-day personalized therapies for nearly all patients.
Unparalleled Early Detection
SeLux NGP detects antibiotic effects on bacteria more rapidly and at lower concentrations than currently possible. This enables bacterial susceptibilities to different antibiotics to be determined virtually simultaneously to the identification of the infecting bacteria.
SeLux’s second-generation platform will deliver same-day personalized therapy results for patients with bacteremia, septicemia, and urinary tract infections. The platform obviates the need for traditional blood and agar cultures by utilizing SeLux NGP’s speed and accuracy.
Works for Broad Menu of Pathogens
No Antibiotic Limitations
SeLux NGP provides a menu of 50+ antibiotics per sample — 5X more antibiotics than current AST technology — and, due to its ready expansion room, will seamlessly incorporate newly-approved drugs.
Works for All Samples
Since effective antibiotic stewardship requires all patients to be rapidly transitioned to targeted therapies, SeLux’s first product is designed to provide rapid results from isolates deriving from all sample types.
SeLux NGP leverages standard microbiology processes so it can easily integrate into clinical microbiology laboratories to rapidly improve antibiotic susceptibility testing efficiencies and speed.
One SeLux system will deliver over 100 AST tests per day, matching standard laboratory susceptibility exceeding the workflow needs of labs.
Designed for frictionless integration in existing labs, SeLux’s breakthrough technology promises superior return on investment to health systems by reducing pharmacy costs, patient length of stay, Hospital Acquired Conditions (HAC), and HAC reduction penalties.